Boothbay Fund Management’s Ionis Pharmaceuticals IONS Stock Holding History

Boothbay Fund Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.49M	Buy	119,700 +88,100	+279%	+$6.63M	0.12%	175
2026 Q1	$2.37M	Buy	31,600 +4,900	+18%	+$387K	0.03%	546
2025 Q4	$2.11M	Buy	26,700 +21,500	+413%	+$1.62M	0.03%	544
2025 Q3	$340K	Buy	+5,200	New	+$254K	﹤0.01%	1378
2021 Q2	–	Sell	-93	Closed	-$418K	–	1971
2021 Q1	$418K	Sell	93 -334	-78%	-$18.6K	0.02%	1030
2020 Q4	$2.41M	Buy	+427	New	+$21.3K	0.09%	225

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Boothbay Fund Management's IONS Position: Q2 2026 in Review

Boothbay Fund Management reduced its Ionis Pharmaceuticals (IONS) stake by 85% in Q2 2026, selling an estimated $4.87M and leaving 11,808 shares worth $936K. The position accounts for 0.01% of the portfolio, ranked #1136.

Boothbay Fund Management first reported a position in IONS in Q3 2025 and has held it in 4 quarters since. The position peaked at $10.7M in Q3 2025. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Boothbay Fund Management held 11,808 shares of Ionis Pharmaceuticals worth $936K as of Q2 2026.
Boothbay Fund Management sold 64,763 Ionis Pharmaceuticals shares in Q2 2026, an estimated $4.87M.
Ionis Pharmaceuticals made up 0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #1136 holding.
Boothbay Fund Management first reported a position in Ionis Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
Boothbay Fund Management's Ionis Pharmaceuticals position peaked at $10.7M in Q3 2025.
515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.